首页 > 市场调查报告书 > 医疗设备

生技设备

市场调查报告书

商品编码

1140752

转染试剂和仪器的全球市场-2022-2029

Global Transfection Reagents and Equipment Market - 2022-2029

出版日期: 2022年10月20日 | 出版商:

DataM Intelligence | 英文 170 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

癌症发病率上升推动市场增长

癌症发病率上升是推动全球转染试剂和设备市场的主要因素之一。例如，根据世卫组织的数据，癌症是全球死亡的主要原因，2020 年全球约有 1000 万人死于癌症。大约三分之一的癌症死亡是由吸烟、高体重指数、饮酒、水果和蔬菜摄入量低以及缺乏身体活动引起的。因此，癌症发病率的增加正在推动市场。

就发病率和死亡率而言，传染病也是一个主要的全球健康问题。传染病是环境、致病和宿主遗传因素的复杂组合，它们在决定对微生物的易感性和感染过程中都发挥着作用。此外，在急诊科就诊后出院时的主要诊断是传染病或寄生虫病的病例越来越多。这样一来，传染病暴发的数量在上升，带动了市场。

此外，近期生物製药行业的专利悬崖更加明显，一些重磅生物药专利即将到期。因此，一些公司已开始投资製造生物仿製药以替代非专利生物製剂，以克服收益递减的威胁。因此，专利到期的威胁刺激了转染技术的采用率，带来了巨大的市场收益。

然而，转染试剂和装置的高成本、试剂插入过程中的风险因素、转染试剂的选择性功效和一定的局限性以及转染技术相关的细胞毒性是製约转染试剂和装置市场的主要因素。

此外，病毒载体随机整合到基因组中，限制了可有效转染的细胞数量，限制了其临床和实验室使用，并带来显着的生物危害风险，是试剂提供的约束的一部分。

地理渗透。

北美是预测期内的主要地区。

由于各种癌症发病率的上升、对蛋白质组学和基因组学技术的需求增加以及政府对预防医学的积极举措，北美在全球转染试剂和设备市场上占据主导地位。癌症发病率的上升预计将提振市场。例如，到 2021 年，美国将有 1,898,160 例新的癌症病例和 608,570 例癌症死亡。因此，越来越多的癌症患者正在推动市场。与预防性医疗保健相关的积极政府举措的存在预计将提振市场。例如，美国癌症协会已投资超过 48 亿美元用于癌症研究，以寻找更好的治疗方法，了解导致癌症的原因，并改善癌症患者的生活质量。国家癌症研究所还开展和支持癌症预防、原因、诊断、治疗、癌症康復、癌症患者护理连续性、健康信息传播等项目的研究，并编制了《国家癌症计划》。因此，政府对预防医学的承诺正在推动市场。筹款和国家科学基金会 (NSF) 等联邦机构为生物技术部门提供大量资金，以开展基于生物技术的研究。此外，预计 NIH 和研究信託基金等国际资助机构将通过为基因研究调查提供资金，在市场增长中发挥重要作用。

竞争格局。

在全球转染试剂和设备市场上运营的主要公司有 Bio-Rad Laboratories, Inc、Merck KGaA、Agilent Technologies、Illumina, Inc、Norgen Biotek Corp、QIAGEN、PerkinElmer Inc、OriGene Technologies Inc、Promega Corporation、Thermo Fisher Scientific Inc。一些主要的关键参与者正在遵循合併和合作战略来扩展他们的业务。例如，2022 年 5 月，Agilent宣布与 APC 就实时过程监控展开合作。通过此次收购，两家公司将结合技术，为客户提供独特的工作流程，支持通过液相色谱进行自动化过程分析。这种合作将增强客户服务和技术。2022 年 2 月，Agilent收购了由 Virtual Control 开发的领先人工智能 (AI) 技术，Virtual Control 是一家人工智能和机器学习软件开发商，为实验室测试创建创新的分析解决方案。此次收购是对数字技术的投资，旨在提高实验室生产力。2021 年 8 月，全球 DNA 测序领域的领导者 Illumina 宣布收购 GRAIL，一家专注于早期检测多种癌症的医疗保健公司，用于“加速患者获得挽救生命的多种癌症早期检测测试”。2022 年 8 月，Merck收购了 Mecaro 的化学品业务，Mecaro 是一家在韩国上市的半导体加热块和化学前体製造商。通过此次收购，默克将扩大其电子业务并进一步提高其区域和全球能力。此次收购包括超过 30 亿欧元的投资。

这份关于全球转染试剂和设备市场的报告提供了大约 61 个市场数据表、51 个数字和 170 页的访问权限。

Market Overview

Transfection Reagents and Equipment Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 7.45 % during the forecast period (2022-2029).

Transfection is a process that involves the production of genetically modified cells with the utilization of foreign nucleic acid (DNA and RNA). Transfection is essential equipment used in investigation studies for gene function and the modulation of gene expression. The transfection reagents and equipment market is driven by the rising incidence of infectious diseases, increase in the R&D expenditure and research activities by the pharmaceutical and biotechnology companies, technological advancements in transfection, increasing incidence of cancer, and the presence of various government initiatives.

Market Dynamics: Increasing incidence of cancer drive market growth.

The rising incidence of cancer is one of the dominating factors propelling the global transfection reagents and equipment market. For instance, According to WHO, cancer is the leading cause of death worldwide and is responsible for around 10 million deaths in 2020 globally. Around one-third of deaths from cancer are due to tobacco use, high body mass index, alcohol consumption, low fruit and vegetable intake, and lack of physical activity. Thus, the rising incidences of cancer are driving the market.

Also, infectious diseases represent a significant health problem worldwide in terms of morbidity and mortality. A complex combination of environmental, pathogen, and host genetic factors plays a role in determining both susceptibilities to microbes and the course of infection. Also, the number of emergency department visits resulting in hospital admission with a principal hospital discharge diagnosis of infectious and parasitic diseases increased. Thus, the rising incidence of infectious diseases is driving the market.

Further, in recent times, the biopharmaceutical industry has seen a significant patent cliff as several blockbuster biologics are facing patent expiration. Consequently, several companies have begun investing in producing biosimilar alternatives to off-patent biologics to overcome the threat of revenue loss. Hence, the patent cliff threat has significantly benefitted the market by spurring the adoption rate of transfection technology.

However, the high cost of transfection reagents and equipment, risk factors during insertion of the reagents, selective effectiveness and certain limitations of transfection reagents and cytotoxic effect associated with transfection technology are the major factors restraining the transfection reagents and equipment market.

The number of cells that the methods can effectively transfect, and the limited clinical and laboratory use, owing to the integration of viral vectors randomly into the genome producing significant bio-hazardous risks, are some of the limitations offered by the transfection reagents.

Market Segmentation: The reagent segment is projected to be the dominant segment in the market during the forecast period.

The reagents segment is sub-segmented into lipid-mediated transfection, DEAE-dextran, activated dendrimers, calcium phosphate, cationic polymers, and others. The reagents segment is expected to dominate the market over the forecast period. It is owing to the increasing commercial adoption rates of these reagents. For instance, OZ Biosciences revolutionized Polyfection with the design of Helix-IN, a novel patented Cationic Hydroxylated Amphiphilic Multi-block Polymer (CHAMP Technology). This novel bi-functional co-polymer is biocompatible, ionizable, pH-responsive, and biodegradable. Thus, the increased adoption of reagents owing to the presence of products is driving the market.

Transfection equipment can be sub-segmented into liposomes, electroporation, microinjection, laserfection, and others.

The equipment segment held a significant market share in the forecast period. The rapidly growing volume of genomics-based research and development initiatives and the introduction of user-friendly products like portable DNA sequencers are expected to propel the transfection reagent and equipment market during the forecast period. The presence of expensive laser-based equipment used for the different transfection methods like laserfection or optoinjection is estimated to drive the growth of the equipment segment.

The transfection reagents and equipment market can be segmented by application into biomedical research, protein production, and therapeutic delivery. Biomedical research is further sub-segmented into gene expression studies, cancer research, and transgenic models.

Biomedical research is expected to boost the market over the forecast period, owing to the increased adoption of reagents for biomedical research. For instance, AltoFect of Altogen biosystems transfection reagent enables the researchers to overcome the challenges and limitations of primary cells and difficult-to-transfect cell lines. Also, Gene expression studies were expected to be the most prominent application. The expansion of the genomic data pool and the growing emphasis on translating genomic information in the clinical workflow lead to a considerable share of this segment. The presence of a substantial number of ongoing research projects that aim at the in-depth investigation of key mechanisms, which underlie chromosomal anomalies, is also supplementing the growth of the segment.

Geographical Penetration: North America is the dominating region during the forecast period.

North America is dominating the global transfection reagents and equipment market owing to the rising incidence of various cancers, the increasing demand for proteomics and genomics technology, and the upfront initiatives taken by the government related to preventive healthcare. The rising incidence of cancer is expected to boost the market. For instance, in 2021, 1,898,160 new cancer cases and 608,570 cancer deaths will occur in the United States. Thus, the growing number of cancer cases is driving the market. The presence of upfront initiatives taken by the government related to preventive healthcare is expected to boost the market. For instance, the American cancer society has invested more than $4.8 billion in cancer research to find more and better treatments, uncover factors that may cause cancer, and improve cancer patients' quality of life. Also, the National Cancer Institute coordinated the National Cancer Program, which conducts and supports the research, health information dissemination, and other programs related to the prevention, cause, diagnosis, and treatment of cancer, rehabilitation from cancer, and continuous care of cancer patients. Thus, government initiatives for preventive healthcare are driving the market. Funding and federal agencies, like the National Science Foundation (NSF), offer the biotechnology sector huge funding to carry out biotechnology-based investigational studies. Moreover, international funding bodies like NIH and Welcome Trust are expected to play a vital role in the market growth by giving the funds for genetic research studies.

Competitive Landscape:

The key players operating in the global transfection reagents and equipment market are Bio-Rad Laboratories, Inc., Merck KGaA, Agilent Technologies, Illumina, Inc., Norgen Biotek Corp., QIAGEN, PerkinElmer Inc., OriGene Technologies Inc., Promega Corporation, and Thermo Fisher Scientific Inc. Some major key players follow merger and collaboration strategies to expand their business. For instance, in May 2022, Agilent announced a collaboration with APC on Real-Time Process Monitoring. Through this acquisition, both companies combined their technologies to provide unique workflows to customers that support automated process analysis via liquid chromatography. This collaboration strengthens services and technologies to the customers. In February 2022, Agilent acquired advanced artificial intelligence (AI) technology developed by Virtual Control, an AI and machine learning software developer that creates innovative analysis solutions in lab testing. This acquisition is an investment in digital technology to improve lab productivity. In August 2021, Illumina, the global leader in DNA sequencing, acquired GRAIL, a healthcare company focused on early life-saving detection of multiple cancers to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection tests. In August 2022, Merck acquired the Chemical Business of Mecaro, a Korea-based and publicly listed manufacturer of heater blocks and chemical precursors for semiconductors. Through this acquisition, Merk expands its Electronics business to further expand its regional capabilities and global capacity. This acquisition includes the investment of more than € 3 billion.

The global transfection reagents and equipment market report would provide an access to approximately 61 market data tables, 51 figures and 170 pages

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

3.1. Market Snippet by Product type
3.2. Market Snippet by Application
3.3. Market Snippet by End-user

4. Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. The increasing incidences of cancer
  - 4.1.1.2. The presence of technological advancements in transfection
- 4.1.2. Restraints
  - 4.1.2.1. The limitations of transfection reagents
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Regulatory Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Unmet Needs

6. By Product type

6.1. Introduction
- 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
- 6.1.2. Market Attractiveness Index, By Product Type Segment
6.2. Reagents*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
  - 6.2.2.1. Lipid mediated transfection
  - 6.2.2.2. DEAE-dextran
  - 6.2.2.3. Calcium phosphate
  - 6.2.2.4. Activated dendrimers
  - 6.2.2.5. Cationic polymers
  - 6.2.2.6. Others
6.3. Equipment
- 6.3.1. Introduction
- 6.3.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
  - 6.3.2.1. Liposomes
  - 6.3.2.2. Electroporation
  - 6.3.2.3. Microinjection
  - 6.3.2.4. Laserfection
  - 6.3.2.5. Others

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application Segment
7.2. Biomedical research*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
- 7.2.3. Cancer research
- 7.2.4. Gene expression
- 7.2.5. Transgenic models
7.3. Protein production
7.4. Therapeutic delivery

8. By End-user

8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user Segment
- 8.1.2. Market Attractiveness Index, By End-user Segment
8.2. Pharmaceutical and biotechnology companies *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
8.3. Research institutes
8.4. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
- 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
- 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. The U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
- 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
- 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. The U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Italy
  - 9.3.6.5. Spain
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
- 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
- 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
- 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
- 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. Australia
  - 9.5.6.5. Rest of Asia Pacific
9.6. The Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
- 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Bio-Rad Laboratories, Inc.*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Key Highlights
- 11.1.4. Financial Overview
11.2. Merck KGaA
11.3. Agilent Technologies
11.4. Illumina, Inc.
11.5. Norgen Biotek Corp.
11.6. QIAGEN
11.7. PerkinElmer Inc.
11.8. OriGene Technologies Inc.
11.9. Promega Corporation
11.10. Thermo Fisher Scientific Inc. (LIST NOT EXHAUSTIVE)

12. Data M

12.1. Appendix
12.2. About Us and Services
12.3. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

转染试剂和仪器的全球市场-2022-2029